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The pathologic increase in the pressure gradient between portal vein and inferior 
venacava is called portal hypertension. Increased portal blood flow and increased 
resistance in the portal venous system cause portal hypertension. The structural com-
ponents and the functional components contribute to the resistance. Hepatic venous 
pressure gradient (HVPG) reflects the degree of portal pressure in liver disease. HVPG 
is calculated as the difference between the wedged hepatic venous pressure (WHVP) 
and the free hepatic venous pressure (FHVP). Clinically significant portal hyperten-
sion (CSPH) is defined as HVPG ≥10. Different values of HVPG have been defined 
as threshold for different consequences of portal hypertension. Variceal hemorrhage, 
portal hypertensive gastropathy, ascites, colopathy, biliopathy and hepatopulmonary 
syndrome are main complications of portal hypertension. Besides nonselective beta 
blockers, other drugs like statins, antioxidants, antidiabetic, anti-inflammatory and 
antiapoptotic drugs have also been seen to be effective in reducing portal pressure.
Keywords: portal hypertension, Hepatic venous pressure gradient (HVPG),  
variceal hemorrhage, hepatopulmonary syndrome, cirrhotic cardiomyopathy
1. Introduction
Vesalius [1] was the person who drew an anatomical picture of the portal venous 
system in 1543 and described a case of bleeding hemorrhoids and suggested that 
this was due to a dilatation of the portal branches. Glisson [2] at a dissection in 
London, in 1650 established that blood was collected from the gastrointestinal tract 
by portal vein and finally to the systemic circulation.
Morgagni described a patient who had died from gastrointestinal hemorrhage: at 
the autopsy, dilatation of the splenic vein and of the short gastric veins were found.
The name cirrhosis was introduced in 1819, in Paris, by Renè Laennec, deriving 
from two words of the antique Greek: Skirros (hard, fibrotic) and Kirrhos (yellow-
ish). He used the word “cirrhosis” in the textbook published by him [3].
Dusaussey [4], wrote an important thesis ‘Studies on esophageal varices in liver 
cirrhosis’, in 1872. He believed that the obstruction to portal flow was a consequence 
of liver cirrhosis.
Gilbert [5] introduced the term portal hypertension in 1902. A ‘pressure close to 
that in the portal vein’ without opening the abdomen, was obtained by puncturing 
one of the dilated abdominal wall veins (the caput medusae) by Davidson [6].
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Thompson (1937) [7] directly measured portal pressure for the first time, with 
the open abdomen, the pressure in the portal vein and in the inferior vena cava. In 
1953 Lebon et al. [8] diagnosed portal hypertension by percutaneous measurement 
of the intrasplenic pressure.
2. Definition
Patients with portal hypertension are identified when they present to hospitals 
or clinic after they have complications such as ascites, gastrointestinal bleeding, 
hepatic encephalopathy or hypersplenism. The pressure gradient between the portal 
vein and the inferior vena cava (the so-called portal perfusion pressure of the liver 
or portal pressure gradient) increases to greater than the normal range of values 
(1–5 mm Hg) when there is pathologic increase in portal pressure, which is called 
portal hypertension [9].
3. Portal pressure measurement and its importance
While evaluating them the need for the evaluating the underlying cirrhosis, the 
degree of portal hypertension, the site of obstruction and the presence of collateral 
circulation makes the diagnosis of portal hypertension complete [10]. As the disease 
progresses, the amount of fibrosis increases and in parallel the portal pressure rises 
corresponding to worsening in the prognosis. Direct or indirect measurement of 
portal pressure can be done with various methods.
Measurement of the hepatic venous pressure gradient (HVPG) is the gold 
standard technique used to quantify the degree portal hypertension in liver 
disease. Diagnosis, classification, and monitoring of portal hypertension, risk 
stratification, identification of candidates for liver resection, and monitoring 
efficacy of β-adrenergic blockers are the main clinical applications of HVPG 
measurements.
HVPG is calculated as the difference between the wedged hepatic venous pres-
sure (WHVP) and the free hepatic venous pressure (FHVP) [11]. The WHVP is 
measured by occluding a main hepatic vein which causes the static column of blood 
to transmit the pressure that is present in the preceding vascular territory i. e. the 
hepatic sinusoids. This measurement, in the absence of presinusoidal obstruction, 
reflects portal pressure [12]. The FHVP is a measure of the pressure of unoccluded 
hepatic vein. HVPG calculated with right atrial pressure shows a worse correlation 
with clinical outcomes, therefore FHVP should be used [13]. There are several 
methods to measure portal pressure as enumerated in Table 1.
The changes in HVPG are due to the alterations in the intrahepatic resistance, 
collateral resistance, portal blood inflow or their combination [14]. Dynamic factors 
such as hepatic vascular tone and mechanical factors such as fibrosis, thrombosis 
and formation of regenerative nodules cause the alterations in HVPG.
The complications of portal hypertension increase as HVPG increases. Clinical 
manifestations and complications occur at a threshold of HVPG of 10 mm Hg, 
which is called clinically significant portal hypertension (CSPH). Different thresh-
olds of HVPG correlate with different prognostic significance (Table 2).
3.1 Technique of measurement of HVPG
Under sedation a balloon-tipped catheter is introduced through the central line 
inserted into the right internal jugular vein, usually under ultrasound guidance [28]. 
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The catheter is advanced through the right atrium into the inferior venacava (IVC) 
under fluoroscopic guidance and then pushed into the right hepatic vein. Alternatively, 
the femoral approach can be used.
SN Methods Procedures
1. Indirect estimation of 
Portal hypertension
Ascitic fluid analysis
Serum Ascitic Albumin Gradient
(SAAG) ≥ 1.1
2. Hepatic Vein Pressure 
Gradient (HVPG)
Open-ended catheter placed in one of the hepatic veins via a 
supraclavicular or internal jugular approach.
Double-lumen balloon catheter placed in the hepatic vein via a 
femoral approach
3. Direct measurement 
of the portal pressure 
gradient
The portal vein can be catheterized directly, either by a trans 
hepatic approach or by a catheter placed via the umbilical vein. 
The added advantage is that collaterals can be embolized while 
this procedure. Angiography can be performed at the same time 
to minimize the number of procedures performed.
Portal pressure measurements should be obtained prior to the 
injection of contrast, which in itself can alter pressures.
4. Intrahepatic portal 
vein pressure
Percutaneous catheterization of an intrahepatic branch of the 
portal vein with a thin Chiba needle; a catheter is passed via the 
intrahepatic branch into the main portal vein.
5. Intrasplenic pressure Placement of a needle percutaneously in the substance of the 
spleen.
6. Umbilical vein 
catheter
Requires dissection to expose the umbilical vein; may require 
dilation of the umbilical vein to facilitate advancement of the 
catheter.
Table 1. 
Different methods of measuring portal pressure.
HVPG Clinical characteristics
< 5 mm Hg Normal
5–10 mm Hg Mild portal hypertension
>6 mm Hg Progression of chronic viral hepatitis [15]
High risk of recurrence after liver transplantation [16]
>10 mm Hg Clinically significant Portal hypertension (CSPH)
>10 mm Hg Esophageal variceal development [17, 18]
Decompensation with ascites [19]
Hepatocellular carcinoma (HCC) [20]
Decompensation after Hepatic resection [21]
>12 mm Hg Variceal bleeding [22, 23]
>16 mm Hg High mortality [24]
>20 mm Hg Failure to control bleeding in acute variceal bleed [25]
Low 1-year survival
>22 mm Hg High mortality in severe alcoholic hepatitis [26]
>30 mm Hg Spontaneous bacterial peritonitis (SBP) [27]
Table 2. 
Different thresholds of hepatic venous pressure gradient (HVPG) correlated with prognostic significance.
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FHVP is obtained after the catheter is maintained in the hepatic vein 2 to 4 cm 
from its takeoff from the IVC. Typically, the difference in pressure between the IVC 
(measured at the hepatic vein ostium) and hepatic vein is ≤1 mmHg. If the differ-
ence is >1 mmHg it means the catheter is placed too deep into the hepatic vein. After 
this, WHVP is measured after the hepatic vein is occluded by inflating the balloon at 
the tip of the catheter. A small amount of contrast dye (5 mL) or carbon dioxide (if 
allergic to the contrast) is injected to confirm that the hepatic vein is occluded so that 
no reflux of the dye above the balloon or should washout via communications with 
other hepatic veins. Around 3 each measurements of wedged and free hepatic venous 
pressure are made each time with the stability of the value for at least 45–60 seconds 
[29]. Finally, the HVPG is calculated by subtracting the FHVP from the WHVP.
The findings of hemodynamic measurements in patients with intrahepatic 
portal hypertension are enumerated [28] in Table 3.
At the same time along with HVPG measurement include transjugular liver 
biopsy, measurement of hepatic blood flow and indocyanine green clearance, 
and wedged hepatic retrograde portography using carbon dioxide can be done. 
Complications during the procedure can be arrhythmia or injury to the local site.
3.2 Noninvasive tests
Though these noninvasive tests cannot replace HVPG measurement for confirm-
ing the diagnosis of portal hypertension, ultrasonogram and transient elastography 
may be helpful.
3.2.1 Ultrasonography
Portal hypertension findings in transabdominal ultrasound are [28]:
• Ascites
• Splenomegaly (> 13 cm or Splenic index >20 cm2)
• Coarse echotexture of liver with irregular margin and dull edge
• Portal flow mean velocity < 12 cm/second
• Reversal of flow in the portal vein and left gastric vein
• Portosystemic collaterals (patent-paraumbilical vein, splenorenal collaterals, 
dilated left and short gastric veins)
• Portal vein diameter > 13 mm
• Decreased or no respiratory variation in splenic and superior mesenteric vein 
diameter
• Portal/splenic/superior mesenteric vein thrombosis
Hemodynamic measurement Presinusoidal Sinusoidal Post-sinusoidal
FHVP (a) Normal Sinusoidal Increased
WHVP (b) Normal or mild increased Increased Increased
HVPG (b-a) Normal or mild increased Increased Normal
Table 3. 
Hemodynamic measurements in portal hypertension.
5
Brief Review of Portal Hypertension Related Complications
DOI: http://dx.doi.org/10.5772/intechopen.96646
3.2.2 Transient elastography
Transient elastography using ultrasound is a noninvasive method for detecting 
hepatic fibrosis. Studies are also looking at it as an option for noninvasively diagnosing 
portal hypertension.
A value <13.6 kPa can be used to rule out portal hypertension, whereas a value 
≥21.1 kPa is likely to have portal hypertension [28].
4. Pathophysiology of portal hypertension
With the concept of physics, it is important to note that portal hypertension is 
related to both flow and resistance.
Pressure (P) equals flow (Q ) times resistance (R), demonstrated by the formula.
 P = Q X R  
Resistance is a function of the length and radius as shown by the formula R = 8n 
L/IIr4, where n is the coefficient of viscosity, L is the length of the vessel, and r is the 
radius. The pathophysiology of portal hypertension is explained in Figure 1.
4.1 Etiology of portal hypertension
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Cytotoxic drugs
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Arteriovenous fistulas (splenic, aorto-mesenteric, aorto-portal, and hepatic 
artery-portal vein)
Formation of collateral circulation connects the portal blood vessels to systemic 
circulation, bypassing the liver and leading to portal hypertension [30]. Sometimes, 
when a pathological process causes occlusion of the splenic vein and the resultant 
Figure 1. 
Pathophysiology of portal hypertension.
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elevated splenic bed venous pressure causes formation of gastric varices which 
can lead to hematemesis it is called sinistral portal hypertension. Sinistral portal 
hypertension is a rare, less than 1%, but life-threatening cause of upper gastric 
bleeding. In fact, the name sinistral portal hypertension is a misnomer since portal 
pressure is usually within the normal range in these cases. Other names for sinistral 
portal hypertension are left sided portal hypertension, segmental, regional, local-
ized, compartmental, lineal, or spleno-portal hypertension [31–33]. It accounts for 
less than 5% of all patients with portal hypertension [33].
Chronic pancreatitis, pancreatic cancer, pancreatic cysts and neuroendocrine 
tumor are common causes of sinistral portal hypertension. Most involved ves-
sel in pancreatitis-related splanchnic vein thrombosis is splenic vein followed by 
portal vein and mesenteric vein. It is mainly related to pancreatic inflammation 
and compression by pancreatic pseudocyst [34]. Around 8% of patients of chronic 
pancreatitis experience splenic vein thrombosis, the majority do not experience any 
form of symptomatic GI bleeding [35]. They present with hypersplenism, abdomi-
nal pain and gastrointestinal bleeding. They should undergo gastroscopy evaluation 
in search of varices. Suspicion of this portal hypertension should be done when 
patient has gastric varices only in fundus with or without any aberrant liver func-
tions or features of liver cirrhosis with the presence of splenomegaly.
Iatrogenic splenic vein injury, ectopic spleen, colonic tumor infiltration, 
peri-renal abscess, post liver transplantation, Hodgkin’s disease, retro-peritoneal 
fibrosis, pancreatic transplantation, and spontaneous thrombus formation are 
among the less common causes of splenic vein thrombosis that can lead to left sided 
hypertension [31, 32].
5. Complications of portal hypertension
Patients with portal hypertension are usually asymptomatic until they develop 
complications. Complications of portal hypertension include:
1. Variceal hemorrhage
2. Portal hypertensive gastropathy (PHG)
3. Ascites
4. Spontaneous bacterial peritonitis
5. Hepatorenal syndrome (HRS)
6. Hepatic hydrothorax
7. Hepatopulmonary syndrome (HPS)
8. Porto-pulmonary hypertension (POPH)
9. Portal hypertensive colopathy
10. Cirrhotic cardiomyopathy
11. Portal Biliopathy
Portal Hypertension - Recent Advances
8
5.1 Variceal hemorrhage
Bleeding occurs in 30%–40% of patients with cirrhosis and varices [36]. The inci-
dence of first variceal bleeding is about 12–15% per year in patients with cirrhosis and 
esophageal varices and mortality ranges from 17% - 57% in patients at first episode 
of variceal bleeding [37]. Carbonell et al. has also estimated mortality during the first 
episode of bleeding to be 15–20% but with Child Pugh C, it is around 30% [38].
The preventive measures advocated are beta blockers and endoscopic variceal 
ligation (EVL). Beta blockers provide protection against rebleeding after index 
hemorrhage while local obliteration of varices is done by EVL.
Nonselective beta blockers have been used daily in patients with cirrhosis and 
portal hypertension with varices either for primary or secondary prophylaxis. 
Recommended agents for primary prophylaxis of variceal hemorrhage are pro-
pranolol and nadolol [39, 40].
Secondary prophylaxis with nonspecific beta blocker (NSBB) has been shown to 
be effective in decreasing both the risk of recurrent bleeding and mortality [41, 42]. 
Without secondary prophylaxis, rebleeding occurs in approximately 60% to 70% of 
patients, usually within one to two years of the index hemorrhagic event [43]. Most 
used NSBB for secondary prophylaxis is propranolol but carvedilol can also be used. 
The decrease in HR at 6 weeks was significantly higher in carvedilol than proprano-
lol group (p = 0.036). The rebleeding at least once within 6 months was also higher 
in propranolol group than carvedilol group (32 vs. 22.7%) [44].
5.2 Portal hypertensive Gastropathy
It is the characteristic appearance which is a mosaic-like pattern or a diffuse, 
erythematous and reticular cobblestone pattern of gastric mucosa consisting of 
small polygonal areas, with or without superimposed red punctate lesions, >2 mm in 
diameter and a depressed white border [45–47]. PHG is classified as mild or severe.
Mild PHG has features like fine pink speckling (scarlatina-type rash), and 
mosaic pattern (snakeskin appearance) and Severe one has discrete red spots or 
diffuse hemorrhagic lesion [48].
The prevalence of PHG in Nepalese population with Chronic Liver Diseases 
(CLD) was 67 percent [49] though it varies significantly from 16 to 100 percentage 
[50]. Acute bleeding in PHG is estimated to occur in 2 to 12 percent [51].
5.3 Ascites
Patients with cirrhosis with portal hypertension may present with ascites leading 
to distension of abdomen and dyspnea. They will have flank fullness with dullness 
on examination. The grading of ascites as graded by International Club for Ascites 
are [52]:
• Grade 1 – Mild ascites detectable only by ultrasound examination
• Grade 2 – Moderate ascites manifested by moderate symmetrical distension of 
the abdomen
• Grade 3 – Large or gross ascites with marked abdominal distension
Ascites may range from mild to refractory. Mild to moderate ascites should 
be managed by modest salt restriction and combination of loop diuretics and 
potassium sparing diuretics.
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Ultrasonographic detection of mild ascites is either pelvic or perihepatic or 
peri splenic ascites, while moderate ascites is presence of pelvic and perihepatic 
and perisplenic ascites, and marked ascites is diffuse ascites in the peritoneal 
cavity [52].
Diuretics should be added in a stepwise fashion along with sodium restriction. 
Gross ascites should be treated with therapeutic paracentesis followed by colloid 
volume expansion, and diuretic therapy. Sometimes refractory ascites is managed 
by repeated large volume paracentesis or insertion of a transjugular intrahepatic 
portosystemic stent shunt (TIPS) [53].
5.4 Spontaneous bacterial peritonitis (SBP)
Spontaneous bacterial peritonitis occurs with a prevalence of 10–25% in cir-
rhotic patients with ascites [54]. It can be community acquired, health care associ-
ated or nosocomial.
Major pathogenic organisms are E. coli (24.3%), followed by Klebsiella pneu-
moniae (12.0%) and Enterococcus faecium (10.5%). Nosocomial SBP has significantly 
higher proportion of Enterococcus (27.7% vs. 6.1%, P < 0.001) than community 
acquired SBP. Nosocomial SBP has a poorer outcome than community acquired 
pneumonia (24.6% vs. 36.8%; P = 0.016). The independent predictors for 30-day 
mortality are nosocomial infection, Child-Pugh classification, hepatocellular 
carcinoma, renal failure and hepatic encephalopathy [54].
Suspicion of nosocomial SBP should be done in a patient with SBP with a 
history of ICU stay during the previous 3 months or on prophylactic antibiotics 
for infection or had antibiotic treatment during previous 3 months or had a recent 
intervention in the hospital setting. Resistance to 3rd generation cephalosporins and 
quinolones has been documented in 40–50% of such cases [55].
Recently, Elsadek et al. found that Patients with SBP (n = 60) have significantly 
higher serum PEC index than those with sterile ascites (n = 118) (41.0/31.2–93.0 
vs. 9.9/5.9–15.0, P < 0.001) and it distinguished culture positive cases significantly 
(P < 0.001) [56].
Diagnostic paracentesis should be performed in all patients who present with 
[57] (1) compatible signs or symptoms (abdominal pain and/or tenderness on 
palpation, fever, and chills); (2) impairment of the hepatic or renal function; (3) 
unexplained hepatic encephalopathy; (4) gastrointestinal bleeding.
SBP is diagnosed by polymorphonuclear cells ≥250 cells/mm3 in ascitic fluid 
in the absence of an intra-abdominal and surgically treatable source of infection. 
Other potential diagnostic methods are leukocyte esterase reagent strips (LERS), 
measurement of leukocyte-derived proteins such as granulocyte elastase and 
lactoferrin, detection of bacterial DNA using polymerase chain reaction (PCR) and 
detecting bacterial DNA in SBP ascites using in situ hybridization [57].
5.5 Hepatorenal syndrome (HRS)
HRS occurs in the setting of advanced cirrhosis and portal hypertension [58] 
with prevalence of 13–45 percentage [59]. It is characterized by peripheral arterial 
vasodilatation and intrarenal vasoconstriction with decrease in renal blood flow 
and renal dysfunction. The most recent proposed diagnostic criteria for HRS-AKI 
are as-.
Diagnostic Criteria for HRS-AKI [60].
• Cirrhosis with ascites; acute liver failure; acute-on-chronic liver failure
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• Increase in serum creatinine ≥0.3 mg/dl within 48 h or ≥ 50% from baseline 
value according to International Club of Ascites (ICA) consensus document 
and/or urinary output ≤0.5 ml/kg B.W. ≥ 6 h*
• No full or partial response, according to the ICA consensus, after at least 2 days 
of diuretic withdrawal and volume expansion with albumin. The recom-
mended dose of albumin is 1 gm/kg of body weight per day to a maximum of 
100 gm/day
• Absence of shock
• No current or recent treatment with nephrotoxic drugs
• Absence of parenchymal disease as indicated by proteinuria >500 mg/day, 
micro-hematuria (>50 red blood cells per high power field), urinary injury 
biomarkers (if available) and/or abnormal renal ultrasonography**.
• Suggestion of renal vasoconstriction with FENa of <0.2% (with levels <0.1% 
being highly predictive)
*The evaluation of this parameter requires a urinary catheter.
**This criterion would not be included in cases of known pre-existing struc-
tural chronic kidney disease (e. g. diabetic or hypertensive nephropathy). AKI, 
acute kidney injury; FENa, fractional excretion of sodium; HRS, hepatorenal 
syndrome.
Nowadays, HRS has been classified as HRS-AKI and HRS-NAKI. The diagnosis.
of HRS-NAKI has been proposed to be made in the context of CKD, or AKD that 
does not meet the criteria for AKI and lasts for <90 days.
HRS-AKD is defined as a percent increase in sCr <50% or as an eGFR <60 min/
ml per 1.73 m2 for <3 months with the fulfillment of the ICA criteria for HRS.
HRS-CKD defined as an eGFR <60 ml/min per 1.73 m2 for ≥3 months with the 
fulfillment of the ICA criteria.
Treatment can be done with terlipressin with albumin as medical treatment or 
with liver transplantation.
5.6 Hepatic hydrothorax
Hepatic hydrothorax (HH) is defined as the excessive (> 500 mL) accumulation 
of transudate fluid in the pleural cavity in patients with decompensated liver cirrho-
sis (LC) with exclusion of cardiopulmonary and pleural diseases [61]. It is present 
in 5–10% of cirrhotic patients. Right sided HH is common accounting for almost 
85% of cases followed by left sided (13%). The mechanism of HH is due to negative 
intrathoracic pressure and liver acting as piston which results the ascitic fluid to 
move from the peritoneal cavity into the pleural space through small defects located 
mainly on the right side of the diaphragmatic tendon [61, 62]. Huang et al. [63] 
classified diaphragmatic defects into four types: (1) Type 1 - no obvious defects; (2) 
Type 2 – blebs lying on the diaphragm; (3) Type 3 – broken defects (fenestrations) 
in the diaphragm; (4) Type 4 – multiple gaps in the diaphragm.
The diagnostic criteria [61] for HH are listed in Table 4.
The options for treatment for refractory HH are low sodium diet with therapeu-
tic thoracocentesis, pleurodesis, mesh repair of diaphragmatic defects, transjugular 
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intrahepatic portosystemic shunt (TIPS), pleuro-venous or peritoneo-venous 
shunting though liver transplantation is the definite therapy.
5.7 Hepato-pulmonary syndrome (HPS)
HPS is defined as a disorder in pulmonary oxygenation, caused by intrapulmonary.
vasodilatation and, less commonly, by pleural and pulmonary arteriovenous 
communications occurring in the clinical setting of portal hypertension. HPS has 
been reported in 10% of patients with chronic viral hepatitis in 15–23% of those 
with cirrhosis and in 28% of those with Budd-Chiari syndrome [64].
The diagnostic criteria for HPS are [64]:
1. Hypoxia with partial pressure of oxygen <80 mmHg or alveolar–arterial oxygen 
gradient ≥15 mmHg in ambient air (≥20 mmHg in patients older than 65 years).
2. Pulmonary vascular defect with positive findings on contrast-enhanced echo-
cardiography (i.e., microbubble opacification of the left heart chambers three 
to six cycles after right atrial passage) or abnormal uptake in the brain (>6%) 
with radioactive lung-perfusion scanning.
Spontaneous resolution of HPS is less likely and the definite treatment is liver 
transplantation however long-term oxygen therapy remains the most frequently 
recommended therapy for symptoms in patients with severe hypoxaemia. No estab-
lished medical therapy is found however some improvement in Pao2 with garlic has 
been seen [65].
5.8 Portopulmonary syndrome (POPH)
Vasoconstriction, vascular remodeling, and proliferative and thrombotic events 
within the pulmonary circulation lead to POPH. The presence of portal hyperten-
sion, hemodynamic measurements of mean pulmonary artery pressure > 25 mmHg 
at rest, mean pulmonary capillary wedge pressure < 15 mmHg, and pulmonary 
vascular resistance >240 dynes/cm−5 confirm POPH [66].
POPH is commonly diagnosed during fifth decade of life, 4–7 years after the 
presence of portal hypertension has been established [67]. Symptoms include 
dyspnea, fatigue, light headedness, and orthopnea in patients with liver cirrhosis 
or portal hypertension. Diuretics can be used for symptomatic control with close 
monitoring. Calcium channel blockers can worsen portal hypertension by causing 
mesenteric vasodilatation.
Criteria Values
Count of white blood cells in pleural fluid
Pleural effusion total protein level
Pleural effusion total protein/serum total protein ratio
Pleural effusion Lactate dehydrogenase (LDH)/serum LDH ratio
Pleural effusion albumin/serum albumin ratio
Pleural effusion bilirubin /serum bilirubin ratio
pH










The diagnostic criteria for hepatic hydrothorax.
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5.9 Portal hypertensive colopathy
Severe portal hypertension can cause lower gastrointestinal bleeding and cause 
anemia. Portal hypertensive colopathy has been defined endoscopically in patients 
with vascular ectasia, redness, and blue vein. Vascular ectasia is classified into two 
types: type 1, solitary vascular ectasia; and type 2, diffuse vascular ectasia. Overall 
portal hypertensive colopathy is found in 2/3rd of the cirrhotic patients including 
solitary vascular ectasia in 36%, diffuse vascular ectasia in 42%, red ness in 21% 
and blue vein in 12 percent [68]. Worsening of Child Pugh class and decrease in 
platelet count increases prevalence of portal hypertensive colopathy in patients with 
liver cirrhosis warranting colonoscopy to prevent lower gastrointestinal bleeding.
5.10 Cirrhotic cardiomyopathy
The diagnostic criteria of cirrhotic cardiomyopathy [69] are enumerated in 
Table 5. Decreased cardiac responsiveness (chronotropic and inotropic incompe-
tence) through the defect in cardiac β-adrenergic receptor signaling is the main 
mechanism for systolic dysfunction in cirrhotic cardiomyopathy. The presence of 
cardiodepressant substances such as nitric oxide (NO) and carbon monoxide (CO) 
and endogenous cannabinoids also play role [70, 71]. Potential mechanisms for 
diastolic dysfunction are alteration in collagen configuration, sodium retention and 
activation of renin angiotensin aldosterone System (RAAS) [72].
Salt and fluid restriction, diuretics and afterload reduction are the aspects of 
treatment in cirrhotic cardiomyopathy. Compared with non-cirrhotics the benefit 
of β-blockers in cirrhotic heart failure is not clear. The use of non-selective β-blocker 
has been shown to reduce prolonged QT interval toward normal values in patients 
with cirrhosis along with some beneficial effect in improving electromechanical 
uncoupling [73]. Possible cure for cirrhotic cardiomyopathy is liver transplantation.
5.11 Portal biliopathy
Presence of biliary abnormalities in patients with non-cirrhotic/non-neoplastic 
extrahepatic portal vein obstruction (EHPVO) and portal cavernoma (PC) is called 
Systolic dysfunction Resting ejection fraction <55%
Blunted increase in cardiac output with exercise or pharmacological stimuli
Diastolic dysfunction Early diastolic atrial filling (E/A ratio) < 1.0 (age corrected)
Deceleration time (DT) > 200 ms
Prolonged isovolumetric relaxation time > 80 ms





Increased brain natriuretic peptide or pro-peptide
Increased troponin I
Table 5. 
Diagnostic criteria for cirrhotic cardiomyopathy.
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portal biliopathy. Compression of bile ducts by PC and/or to ischemic damage sec-
ondary to an altered biliary vascularization in EHPVO and PC leads to contribution 
of this complication.
Normally, epicholedochal venous plexus of Saint and the paracholedochal plexus 
of Petren, whose normal diameter does not exceed 1 mm, are responsible for the 
venous drainage of the biliary tree. Dilation of plexus of Saint causes fine irregulari-
ties in biliary walls while dilation of plexus of Petren causes extrinsic compression in 
chronic portal vein obstruction. Patients present with jaundice, cholangitis, cholecys-
titis, abdominal pain, and cholelithiasis. Around 5%–38% of patients develop biliary 
symptoms [74]. Dhiman et al. [75] identified four stages in PB progression (Table 6).
On the aspect of treatment, surgical porto-systemic shunt or transjugular 
intrahepatic porto-systemic shunt can be performed, and treatment on the biliary 
stenosis includes endoscopic (Endoscopic retrograde cholangiopancreatography 
with endoscopic sphincterotomy, balloon dilation, stone extraction, stent place-
ment) and surgical (bilioenteric anastomosis, cholecystectomy) approaches are 
used for decompression of portal cavernoma.
6. Future perspectives
Besides different surgeries with portosystemic shunting, there are newer drugs 
developed for reduction of portal pressure. Few drugs which have been seen to be 
beneficial are:
6.1 Farnesoid X receptor (FXR) agonists
Obeticholic acid (OCA), a semisynthetic FXR agonist tested in preclinical 
models of cirrhosis has shown beneficial effects as transcriptional modulator on PH 
by reducing the intrahepatic vascular resistance (IHVR) [76].
6.2 Statins
Statins have antioxidative, antiproliferative and anti-inflammatory effects, and 
can improve endothelial dysfunction [77].
They have shown strong hepatosinusoidal protective effects in preclinical 
models of chronic liver diseases, ultimately leading to reduction in portal pressure 
[78, 79]. Simvastatin has shown beneficial effects when administered alone or 







Preclinic Yes No Normal No No





Symptomatic Yes Advanced 
changes
Abnormal yes No




Characteristics of four stages in portal biliopathy natural history.
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6.3 Anti-apoptotic drugs
Emricasan has been seen to improve portal pressure and IHVR compared with 
vehicle-treated rats, in addition to improved liver function and microcirculation, 
and finally with improved liver sinusoidal endothelial cell (LSEC) and hepatic stel-
late cells (HSC) phenotype and reduced inflammation [82].
6.4 Anticoagulants
Rivaroxaban, direct inhibitor of factor Xa has been shown to reduce liver 
microthrombosis, HSC activation and portal pressure in experimental models of 
cirrhosis [83].
6.5 Antidiabetic drugs
Liraglutide has shown antifibrotic effects in NASH patients, thus with high 
probabilities of success as a treatment for portal hypertension and chronic liver 
disease [84]. Metformin has shown to improve liver hemodynamic and fibrosis by a 
reduction in inflammation and oxidative stress [85].
6.6 Anti-inflammatory agents
Anti-inflammatory drugs such as rapamycin have reduced portal pressure in rats 
with Portal hypertension due to its intrahepatic and extrahepatic effects [86, 87].
6.7 Taurine
Taurine has pleiotropic effects. A small cohort of patients with clinically signifi-
cant PH (HVPG >12 mmHg) has reported reduction in portal pressure [88]. Thus, 
consumption of low carbonated ‘energy drinks’ rich in taurine may have a positive 
impact in portal hypertension.
7. Conclusion
Portal Hypertension is responsible for many complications in liver cirrhosis. 
Reduction of portal pressure decreases the rate of complications in advanced liver dis-








Nepal Police Hospital, Kathmandu, Nepal
*Address all correspondence to: abhamal@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Portal Hypertension - Recent Advances
[1] Vesalius A. De Humani corporis 
fabrica. Basileae, 1543
[2] Glisson F. The portal circulation. In: 
Child G. N Engl J Med 1955; 252:837
[3] Genoveffa Balducci, Antonio 
V Sterpetti and Marco Ventura. A 
short history of portal hypertension 
and of its management. Journal of 
Gastroenterology and Hepatology 31 
(2016) 541-545
[4] Dusaussey M. Etudes sur les 
varices de l'oesophage dans la cirrhose 
hepatique. These, Paris, 1877
[5] Gilbert A, Carnot P. Les fonctions 
hepatiques. Paris, 1902
[6] Davidson CS, Gibbons TB, 
Faloon WW. Systemic and portal venous 
pressures in cirrhosis of the liver. J Lab 
Clin Med 1950; 35:181
[7] Thompson WP, Caughley GL, 
Whipple AO et al. Splein vein pressure 
in congestive splenomegaly. J. Clin. 
Invest. 1937; 16: 571-576.
[8] Lebon J, Fabregoule M, Eisenbeth H 
et al. Splenoportographie transperietale. 
Alg Med 1953; 57: 105-110.
[9] Abraldes JG, Sarlieve P, Tandon P. 
Measurement of portal pressure. Clinics 
in liver disease. 2014 Nov 1;18(4):779-792.
[10] John C. Hoefs, et al. Diagnosis and 
hemodynamic assessment of portal 
hypertension. Surgical Clinics of North 
America-Vol. 70, No.2, April 1990
[11] Bosch J, Abraldes JG, Berzigotti A,  
et al. The clinical use of HVPG 
measurements in chronic liver disease. 
Nat Rev Gastroenterol Hepatol 2009;6: 
576-582.
[12] Groszmann RJ, Glickman M, 
Blei AT, et al. Wedged and free hepatic 
venous pressure measured with a 
balloon catheter. Gastroenterology 
1979;76(2):253-258.
[13] La Mura V, Abraldes JG, Berzigotti A, 
et al. Right atrial pressure is not adequate 
to calculate portal pressure gradient 
in cirrhosis: a clinical-hemodynamic 
correlation study. Hepatology 2010; 
51(6):2108-2116.
[14] Abraldes JG, Araujo IK, Turon F, et 
al. Diagnosing and monitoring cirrhosis: 
liver biopsy, hepatic venous pressure 
gradient and elastography. Gastroenterol 
Hepatol 2012;35(7):488-495.
[15] Kumar M, Kumar A, Hissar S et al. 
Hepatic venous pressure gradient as 
a predictor of ¢ brosis in chronic liver 
disease because of hepatitis B virus. 
Liver Int 2008; 28: 690-698.
[16] Blasco A, Forns X, Carrion JA et 
al. Hepatic venous pressure gradient 
identifies patients at risk of severe 
hepatitis C recurrence after liver 
transplantation. Hepatology 2006; 43: 
492-499.
[17] Garcia-Tsao G, Groszmann RJ, 
Fisher RL et al. Portal pressure, presence 
of gastroesophageal varices and variceal 
bleeding. Hepatology 1985; 5: 419-424.
[18] Groszmann RJ, Garcia-Tsao G, 
Bosch J et al. Beta-blockers to prevent 
gastroesophageal varices in patients 
with cirrhosis. N Engl J Med 2005; 
353:2254-2261.
[19] Ripoll C, Groszmann R, Garcia-Tsao 
G et al. Hepatic venous pressure gradient 
predicts clinical decompensation in 
patients with compensated cirrhosis. 
Gastroenterology 2007; 133:481-488.
[20] Ripoll C, Groszmann RJ, Garcia-
Tsao G et al. Hepatic venous pressure 
gradient predicts development of 
hepatocellular carcinoma independently 
References
17
Brief Review of Portal Hypertension Related Complications
DOI: http://dx.doi.org/10.5772/intechopen.96646
of severity of cirrhosis. J Hepatol 2009; 
50: 923-928.
[21] Berzigotti A, Reig M, Abraldes JG et 
al. Portal hypertension and the outcome 
of surgery for hepatocellular carcinoma 
in compensated cirrhosis: a systematic 
review and meta-analysis. Hepatology 
2015; 61: 526-536
[22] Habib A, Sanyal AJ. Acute variceal 
hemorrhage. Gastrointest Endosc Clin N 
Am 2007; 17:223-252, v.
[23] De Franchis R, Dell'Era A, 
Iannuzzi F. Diagnosis and treatment 
of portal hypertension. Dig Liver Dis. 
2004; 36:787-798.
[24] Silva-Junior G, Baiges A, Turon F 
et al. The prognostic value of hepatic 
venous pressure gradient in patients 
with cirrhosis is highly dependent 
on the accuracy of the technique. 
Hepatology 2015; 62:1584-1592.
[25] Abraldes JG, Villanueva C, Banares 
R ~ et al. Hepatic venous pressure 
gradient and prognosis in patients with 
acute variceal bleeding treated with 
pharmacologic and endoscopic therapy. 
J Hepatol 2008;48: 229-236.
[26] Rincon D, Lo Iacono O, Ripoll 
C et al. Prognostic value of hepatic 
venous pressure gradient for in-hospital 
mortality of patients with severe acute 
alcoholic hepatitis. Aliment Pharmacol 
Ther 2007; 25:841-848.
[27] Serste T, Bourgeois N, Lebrec D,  
Evrard S, Devière J, Le Moine O. 
Relationship between the degree of 
portal hypertension and the onset of 
spontaneous bacterial peritonitis in 
patients with cirrhosis. Acta gastro-
enterologica Belgica. 2006;69(4):355.
[28] Berzigotti A, Seijo S, Reverter E, 
Bosch J, Bosch, Groszmann; Portal 
Hypertension Collaborative Group, 
Casado, García-Pagán, Fernández, 
Roskams. Assessing portal hypertension 
in liver diseases. Expert review of 
gastroenterology & hepatology. 2013 
Feb 1;7(2):141-155.
[29] Groszmann RJ, Wongcharatrawee S. 
The hepatic venous pressure gradient: 
anything worth doing should be  
done right. Hepatology. 2004 Feb;39(2): 
280-283.
[30] Bosch J, Navasa M, Garcia-Pagan JC, 
Delacy AM, Rodes J: Portal hypertension. 
Med Clin North Am 1989; 73:931-953.
[31] Thompson R, Taylor M, McKie L,  
Diamond T. Sinistral Portal Hyper-
tension. Ulster Med J. 2006; 75 (3) 
175-177.
[32] Singhal D, Kakodkar R, Soin A, 
Gupta S, Nundy S. Sinistral Portal 
Hypertension. A Case Report. JOP. 
2006; 7(6):670-667.
[33] Koklu S, Coban S, Yuksel O, Arhan M. 
Left-Sided Portal Hypertension. Dig Dis 
Sci. 2007; 52:1141-1149
[34] Li ZS, Tang CW, Qian JM, 
Yuan YZ, Wang XP. Practice guidance 
for diagnosis and treatment of 
pancreatitis-related splanchnic vein 
thrombosis (Shenyang, 2020). Journal 
of Digestive Diseases. 2020 Nov 20.
[35] Adams DB, Mauterer DJ, Vujic IJ, 
Anderson MD. Preoperative control of 
splenic artery inflow in patients with 
splenic venous occlusion. South Med J. 
1990; 83:1021-1024.
[36] Habib A, Sanyal AJ. Acute variceal 
hemorrhage. Gastrointest Endosc Clin N 
Am 2007; 17:223-252, v.
[37] Zaman A. Current Management of 
Esophageal Varices. Curr Treat Options 
Gastroenterol 2003; 6:499-507
[38] Carbonell N, Pauwels A, Serfaty L, 
Fourdan O, Lévy VG, Poupon R.et 
al. Improved survival after variceal 
bleeding in patients with cirrhosis over 
Portal Hypertension - Recent Advances
18
the past two decades. Hepatology2004; 
40:652-659.
[39] Castaneda B, Debernardi-Venon W, 
Bandi JC Andreu V, Pérez-del-Pulgar S, 
Moitinho E, Pizcueta P, Bosch J.et al. The 
role of portal pressure in the severity 
of bleeding in portal hypertensive rats. 
Hepatology2000; 31:581-586
[40] Russo MW. Variceal Bleeding. Curr 
Treat Options Gastroenterol. 2002; 
5:471-477.
[41] Bernard B, Lebrec D, Mathurin P, 
Opolon P, Poynard T. Beta-adrenergic 
antagonists in the prevention of gastro-
intestinal rebleeding in patients with 
cirrhosis: a meta-analysis. Hepatology 
1997; 25:63-70.
[42] De Franchis R. Evolving consensus 
in portal hypertension. Report of the 
Baveno IV consensus workshop on 
methodology of diagnosis and therapy 
in portal hypertension. J Hepatol 2005; 
43:167-176
[43] Bosch J, Garcia-Pagan JC. Prevention 
of variceal rebleeding. Lancet 2003; 
361:952-954.
[44] Hamal AB, KC S, Thapa P, 
Sharma D, Karki N, et al. Carvedilol 
Versus Propranolol for Secondary 
Prophylaxis of Variceal Hemorrhage in 
Patients with Liver Cirrhosis. Adv Res 
Gastroentero Hepatol, 2020; 15(4):  
555920.
[45] Kamath PS, Shah VH: Portal 
Hypertension and Bleeding Esophageal 
Varices. Zakim and Boyer’s Hepatology: 
A Textbook of Liver Disease (6th ed). 
In Boyer TD, Manns MP, Sanyal AJ (ed): 
Elsevier Saunders, Philadelphia; 2012. 
296-326.
[46] Feldman M, Lee EL: Pathophysiology, 
Diagnosis, Management. Sleisenger 
and Fordtran’s Gastrointestinal and 
Liver Disease (10th ed). In: Feldman M, 
Friedman LS, Brandt LJ (ed): Elsevier 
Saunders, Philadelphia; 2010. 868-883
[47] Vigneri S, Termini R, Piraino A, 
Scialabba A, Pisciotta G, Fontana N: The 
stomach in liver cirrhosis. Endoscopic, 
morphological, and clinical correlations. 
Gastroenterology. 1991,101:472-478.
[48] McCormack TT, Sims J,  
Eyre-Brook I, Kennedy H, Goepel J, 
Johnson AG, Triger DR: Gastric lesions 
in portal hypertension: inflammatory 
gastritis or congestive gastropathy? Gut. 
1985,26:1226-1232.
[49] Tiwari P S, Kc S, Sharma D, et al. 
(August 21, 2019) Prevalence of Portal 
Hypertensive Gastropathy in Chronic 
Liver Disease and Correlation with 
the Severity of Liver disease. Cureus 
11(8): e5454.
[50] Gjeorgjievski M, Cappell MS: Portal 
hypertensive gastropathy: a systematic 
review of the pathophysiology, clinical 
presentation, natural history and therapy. 
World J Hepatol. 2016, 8:231-262.
[51] Primignani M, Carpinelli L,  
Preatoni P, Battaglia G, Carta A, 
Prada A, Cestari R, Angeli P, Gatta A, 
Rossi A, Spinzi G. Natural history 
of portal hypertensive gastropathy 
in patients with liver cirrhosis. 
Gastroenterology. 2000 Jul 1; 119(1): 
181-187.
[52] Bates JA. Abdominal Ultrasound. 
2nd ed. Edinburgh: Churchill 
Livingstone; 2004. p. 97-107.
[53] Moore KP, Wong F, Gines P, 
Bernardi M, Ochs A, Salerno F, Angeli P, 
Porayko M, Moreau R, Garcia-Tsao G, 
Jimenez W. The management of ascites 
in cirrhosis: report on the consensus 
conference of the International 
Ascites Club. Hepatology. 2003 Jul 
1;38(1):258-266.
[54] Ding X, Yu Y, Chen M, Wang C, 
Kang Y, Lou J. Causative agents and 
outcome of spontaneous bacterial 
peritonitis in cirrhotic patients: 
community-acquired versus nosocomial 
19
Brief Review of Portal Hypertension Related Complications
DOI: http://dx.doi.org/10.5772/intechopen.96646
infections. BMC infectious diseases. 
2019 Dec 1; 19(1):463.
[55] Acharya SK. Difficult to treat 
spontaneous bacterial peritonitis. 
Tropical Gastroenterology. 2013 May 
18;34(1):7-13.
[56] Elsadek HM, Elhawari SA, 
Mokhtar A. A novel serum index for 
accurate diagnosis of spontaneous 
bacterial peritonitis in cirrhotic patients 
without other infections. Egyptian Liver 
Journal. 2020 Dec; 10(1):1-8.
[57] Enomoto H, Inoue SI, Matsuhisa A, 
Nishiguchi S. Diagnosis of spontaneous 
bacterial peritonitis and an in situ 
hybridization approach to detect an 
“unidentified” pathogen. International 
journal of hepatology. 2014 Jan 1; 2014.
[58] Epstein M. Hepatorenal 
syndrome: emerging perspectives of 
pathophysiology and therapy. J Am Soc 
Nephrol JASN. 1994 Apr;4(10):1735-1753
[59] Low G, Alexander GJM, Lomas DJ. 
Hepatorenal Syndrome: Aetiology, 
Diagnosis, and Treatment [Internet]. 
Gastroenterology Research and Practice. 
2015.
[60] Angeli P et al. News in patho-
physiology, definition and classification 
of hepatorenal syndrome: A step beyond 
the International Club of Ascites (ICA) 
consensus document. J Hepatol (2019).
[61] Garbuzenko DV, Arefyev NO. 
Hepatic hydrothorax: An update and 
review of the literature. World J Hepatol 
2017; 9(31): 1197-1204
[62] Lazaridis KN, Frank JW, Krowka MJ,  
Kamath PS. Hepatic hydrothorax: 
pathogenesis, diagnosis, and manage ent. 
Am J Med 1999; 107: 262-267.
[63] Huang PM, Chang YL, Yang CY,  
Lee YC. The morphology of 
diaphragmatic defects in hepatic 
hydrothorax: thoracoscopic finding. 
J Thorac Cardiovasc Surg 2005; 130: 
141-145.
[64] The European Association for 
the Study of the Liver. EASL Clinical 
Practice Guidelines for the management 
of patients with decompensated 
cirrhosis. J Hepatol (2018), https://doi.
org/10.1016/j.jhep.2018.03.024.
[65] De BK, Dutta D, Pal SK, 
Gangopadhyay S, Das Baksi S, Pani A. 
The role of garlic in hepatopulmonary 
syndrome: a randomized controlled trial. 
Can J Gastroenterol 2010; 24:183-188.
[66] Porres-Aguilar M, Gallegos-Orozco 
JF, Garcia H, Aguirre J, Macias-
Rodriguez RU, Torre-Delgadillo A. 
Pulmonary vascular complications in 
portal hypertension and liver disease: 
a concise review. Rev Gastroenterol 
Mex. 2013;78(1):35-44. doi: 10.1016/j. 
rgmx.2012.10.004.
[67] Hadengue A, Benhayoun MK, 
Lebrec D, Benhamou JP. Pulmonary 
hypertension complicating portal 
hypertension: prevalence and relation 
to splanchnic hemodynamics. 
Gastroenterology. 1991 Feb 1; 100(2): 
520-528.
[68] Ito K, Shiraki K, Sakai T,  
Yoshimura H, Nakano T. Portal 
hypertensive colopathy in patients 
with liver cirrhosis. World Journal of 
Gastroenterology: WJG. 2005 May 28; 
11(20):3127.
[69] Wiese S, Hove JD, Bendtsen F, 
Møller S. Cirrhotic cardiomyopathy: 
pathogenesis and clinical relevance. 
Nature reviews Gastroenterology & 
hepatology. 2014 Mar;11(3):177.
[70] Baldassarre M, Giannone FA, 
Napoli L, Tovoli A, Ricci CS, Tufoni M, 
et al. The endocannabinoid system 
in advanced liver cirrhosis: 
pathophysiological implication and 
future perspectives. Liver Int. 2013;33: 
1298-1308.
Portal Hypertension - Recent Advances
20
[71] Van Obbergh L, Vallieres Y, Blaise G. 
Cardiac modifications occurring in 
the ascitic rat with biliary cirrhosis are 
nitric oxide related. J Hepatol. 1996;24: 
747-752.
[72] Wong F. Cirrhotic cardiomyopathy. 
Hepatol Int. 2009; 3:294-304.
[73] Henriksen JH, Bendtsen F,  
Hansen EF, Moller S. Acute non-
selective beta-adrenergic blockade 
reduces prolonged frequency-adjusted 
Q-T interval (QTc) in patients with 
cirrhosis. J Hepatol. 2004; 40:239-246.
[74] Franceschet I, Zanetto A,  
Ferrarese A, Burra P, Senzolo M. 
Therapeutic approaches for portal 
biliopathy: A systematic review. 
World J Gastroenterol. 2016 Dec 7; 
22(45):9909-9920.
[75] Dhiman RK, Saraswat VA, Valla DC,  
Chawla Y, Behera A, Varma V, 
Agarwal S, Duseja A, Puri P, Kalra N, 
et al. Portal cavernoma cholangiopathy: 
consensus statement of a working party 
of the Indian national association for 
study of the liver. J Clin Exp Hepatol. 
2014;4: S2–S14.
[76] Verbeke L, Farre R, Trebicka J, 
Komuta M, Roskams T, Klein S, Elst IV, 
Windmolders P, Vanuytsel T, Nevens F, 
Laleman W. Obeticholic acid, a farnesoid 
X receptor agonist, improves portal 
hypertension by two distinct pathways 
in cirrhotic rats. Hepatology. 2014 Jun; 
59(6):2286-2298.
[77] Pose E, Trebicka J, Mookerjee RP, 
Angeli P, Ginès P. Statins: old drugs as 
new therapy for liver diseases? Journal 
of hepatology. 2019 Jan 1;70(1):194-202.
[78] Trebicka J, Hennenberg M, 
Laleman W, et al. Atorvastatin lowers 
portal pressure in cirrhotic rats by 
inhibition of RhoA/Rho-kinase and 
activation of endothelial nitric oxide 
synthase. Hepatology 2007; 46: 242-253.
[79] Abraldes JG, Rodríguez-Vilarrupla A, 
Graupera M, et al. Simvastatin treatment 
improves liver sinusoidal endothelial 
dysfunction in CCl4 cirrhotic rats. J 
Hepatol 2007; 46: 1040-1046.
[80] Pollo-Flores P, Soldan M, Santos UC, 
et al. Three months of simvastatin 
therapy vs. placebo for severe portal 
hypertension in cirrhosis: a randomized 
controlled trial. Dig Liver Dis 2015; 47: 
957-963.
[81] Abraldes JG, Villanueva C, Aracil C, 
et al. Addition of simvastatin to standard 
therapy for the prevention of variceal 
rebleeding does not reduce rebleeding 
but increases survival in patients with 
cirrhosis. Gastroenterology 2016; 150: 
1160-1170.e3
[82] Gracia-Sancho J, Contreras PC, Vila S, 
et al. The pan caspase inhibitor emricasan 
improves the hepatic microcirculatory 
dysfunction of CCl4-cirrhotic rats leading 
to portal hypertension amelioration and 
cirrhosis regression. Hepatology 2016; 64: 
811-1050.
[83] Vilaseca M, García-Calderó H, 
Lafoz E, et al. The anticoagulant 
rivaroxaban lowers portal hypertension 
in cirrhotic rats mainly by deactivating 
hepatic stellate cells. Hepatology 2017; 
65: 2031-2044.
[84] Armstrong MJ, Gaunt P, Aithal GP, 
et al. Liraglutide safety and efficacy 
in patients with non-alcoholic 
steatohepatitis (LEAN): a multicentre, 
double-blind, randomised, placebo-
controlled phase 2 study. Lancet 2016; 
387: 679-690.
[85] Tripathi DM, Erice E, Lafoz E, et al. 
Metformin reduces hepatic resistance 
and portal pressure in cirrhotic rats. 
Am J Physiol Gastrointest Liver Physiol 
2015; 309: G301–G309.
[86] Wang W, Yan J, Wang H, et al. 
Rapamycin ameliorates inflammation 
and fibrosis in the early phase of 
21
Brief Review of Portal Hypertension Related Complications
DOI: http://dx.doi.org/10.5772/intechopen.96646
cirrhotic portal hypertension in rats 
through inhibition of mTORC1 but not 
mTORC2. PLoS One 2014; 9: e83908.
[87] Mejias M, Garcia-Pras E, Gallego J, 
et al. Relevance of the mTOR signaling 
pathway in the pathophysiology of 
splenomegaly in rats with chronic 
portal hypertension. J Hepatol 2010; 52: 
529-539.
[88] Schwarzer R, Kivaranovic D,  
Mandorfer M, Paternostro R,  
Wolrab D, Heinisch B, Reiberger T,  
Ferlitsch M, Gerner C, Trauner M, 
Peck-Radosavljevic M. Randomised 
clinical study: the effects of oral 
taurine 6 g/day vs placebo on portal 
hypertension. Alimentary pharmacology 
& therapeutics. 2018 Jan; 47(1):86-94.
